Render Target: STATIC
Render Timestamp: 2024-10-04T09:49:19.479Z
Commit: f04ddd7fea9fb3592f59f61482fcb94610d25cbe
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

DDX39A (F7T4J) Rabbit mAb #47857

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H M R Mk
    SENSITIVITY Endogenous
    MW (kDa) 49
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 
    • Mk-Monkey 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    DDX39A (F7T4J) Rabbit mAb recognizes endogenous levels of total DDX39A protein. This antibody does not cross-react with UAP56 protein.

    Species Reactivity:

    Human, Mouse, Rat, Monkey

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro22 of human DDX39A protein.

    Background

    The UAP56 gene is found in the central MHC region and encodes a member of the DEAD-box family of RNA helicases (1). Also known as DDX39B and BAT1, UAP56 functions as an ATP-dependent splicing factor and RNA helicase in the evolutionary conserved transcription/export (TREX) complex. The TREX complex is recruited to sites of active transcription, where it travels along the length of the gene with RNA polymerase II and exports resulting mRNAs to the cytoplasm (2-8).

    DDX39, also known as DDX39A, is a DEAD-box helicase highly homologous to UAP56 and is upregulated in lung squamous cell cancers (9,10). DDX39 has been shown to bind to TRF2 to regulate telomere protection (11). Furthermore, DDX39 is overexpressed in several cancer types, which is associated with poor prognosis (12-15). Both UAP56 and DDX39 are hijacked by various viral replication machineries to enable viral reproduction and mRNA export (16-18). UAP56 and DDX39 have also been implicated in promoting the AR-V7 splice variant in advanced prostate cancers (19).
    1. Peelman, L.J. et al. (1995) Genomics 26, 210-8.
    2. Fleckner, J. et al. (1997) Genes Dev 11, 1864-72.
    3. Strässer, K. et al. (2002) Nature 417, 304-8.
    4. Custódio, N. et al. (2004) RNA 10, 622-33.
    5. Kapadia, F. et al. (2006) Gene 384, 37-44.
    6. Shen, J. et al. (2007) J Biol Chem 282, 22544-50.
    7. Kota, K.P. et al. (2008) J Cell Sci 121, 1526-37.
    8. Majerciak, V. et al. (2010) Virology 407, 206-12.
    9. Sugiura, T. et al. (2007) Exp Cell Res 313, 782-90.
    10. Sugiura, T. et al. (2007) Cancer Biol Ther 6, 957-64.
    11. Yoo, H.H. and Chung, I.K. (2011) Aging Cell 10, 557-71.
    12. Kikuta, K. et al. (2012) J Proteomics 75, 1089-98.
    13. Kuramitsu, Y. et al. (2013) Anticancer Res 33, 2557-60.
    14. Kuramitsu, Y. et al. (2013) Anticancer Res 33, 3133-6.
    15. Xing, C. et al. (2020) Front Oncol 10, 1261.
    16. Dufu, K. et al. (2010) Genes Dev 24, 2043-53.
    17. Zielke, B. et al. (2011) J Virol 85, 1804-19.
    18. Wisskirchen, C. et al. (2011) J Virol 85, 8646-55.
    19. Nakata, D. et al. (2017) Biochem Biophys Res Commun 483, 271-276.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.